Intellia Therapeutics Inc (NTLA) Stock Analysis
Verdict: AVOID
Persistent cash burn and heavy insider selling outweigh clinical promise, making current price levels a falling knife rather than a floor.
Investment score: 38/100
Analysis as of
Is Intellia Therapeutics Inc stock worth reviewing? AI model thesis
The AI model classifies NTLA as a high-risk cash burner. While the science is transformative, the balance sheet trend is unsustainable without significant dilution or partner milestones. Recent price action and insider behavior suggest further downside.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 25/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 60/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 55/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
Intellia Therapeutics Inc opportunities and risks
What speaks for NTLA
- Curative Potential of NTLA-2001
What speaks against NTLA
- Immediate Capital Depletion and Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| NTLA | n/a | 17.4x | n/a | -153.7% | -597.0% | -31.6% |
| ZYME | n/a | 20.3x | n/a | 94.4% | -126.3% | -4.7% |
| ANAB | n/a | 9.8x | 39.4x | 116.4% | -11.5% | 0.2% |
| RXRX | n/a | 23.1x | n/a | -34.4% | -844.5% | -21.3% |
| FBRX | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.8% |
| VIR | n/a | 22.0x | n/a | 275.2% | -676.0% | -30.8% |
| Peer median | n/a | 20.3x | n/a | 94.4% | -126.3% | -4.7% |
Frequently asked questions about Intellia Therapeutics Inc (NTLA)
Is NTLA stock a good investment?
The cached TradeMates AI model rates Intellia Therapeutics Inc as AVOID with an investment score of 38/100. The AI model classifies NTLA as a high-risk cash burner. While the science is transformative, the balance sheet trend is unsustainable without significant dilution or partner milestones. Recent price action and insider behavior suggest further downside. This is algorithmic model output, not personal investment advice.
Is NTLA stock a buy?
The TradeMates model verdict for NTLA is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.